Traumatic brain injury For decades, preclinical and small clinical studies have investigated the effect of citicoline when provided intravenously, intramuscularly, or orally in the management of traumatic brain injury (TBI)
It also induces the reverse transport of these transporters (Sulzer et al., 1995), leading to the release of monoamines from the neuronal cytoplasm into the synaptic cleft (McCann et al., 1998)
In September 2022, Eli Lilly published the results of its preclinical studies on LY3437943 in the journal Cell Metabolism, in an article titled "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." In vitro and in vivo validation of the triple agonist effect of LY3437943: Eli Lilly's research results show that LY3437943 demonstrates superior weight loss effects compared to GLP-1 receptor (GLP-1R) selective agonists (GLP-1 RA), GLP-1R and GCGR dual agonists (Cotadutide or 05677), and GLP-1R and GIPR dual agonists
K-beauty cleanser category fits double cleansing